Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Chief Operating Officer | September 04, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date September 04, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 177,184 |
Reported balance
After 2026-09-04 transaction · row 1
1 source rowRow 1 · 2026-09-04 · Tax withholding · Disposed 24,799 · Balance 177,184 F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $155.99 | $0.00 |
DisclosureSEC source: 0001209191-23-017408 · doc4.xml · derivative · entry 3 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2033-03-06 F3 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017408 · doc4.xml · nonDerivative · entry 2 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,423 F2 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,370 | $157.21 | $215,377.70 |
DisclosureSEC source: 0001209191-23-017408 · doc4.xml · nonDerivative · entry 1 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,923 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 378 | $147.57 | $55,781.46 |
DisclosureSEC source: 0001209191-23-016055 · doc4.xml · nonDerivative · entry 1 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,293 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to sell) · Derivative | 48,000 | $0.00 Strike: $80.42 | $0.00 |
DisclosureSEC source: 0001209191-22-017347 · doc4.xml · derivative · entry 4 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2032-03-07 F4 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017347 · doc4.xml · nonDerivative · entry 3 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,671 F3 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 398 | $79.36 | $31,585.28 |
DisclosureSEC source: 0001209191-22-017347 · doc4.xml · nonDerivative · entry 2 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,671 F2 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 5, 2018. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,308 | $79.20 | $103,593.60 |
DisclosureSEC source: 0001209191-22-017347 · doc4.xml · nonDerivative · entry 1 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,069 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 376 | $75.05 | $28,218.80 |
DisclosureSEC source: 0001209191-22-014408 · doc4.xml · nonDerivative · entry 1 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,377 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,623 | $78.29 | $127,064.67 |
DisclosureSEC source: 0001209191-21-055383 · doc4.xml · nonDerivative · entry 1 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,753 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock. Read SEC document |
| March 05, 2021 Filed Mar 11, 2021 01:00 UTC Amendment | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 347 | $84.65 | $29,373.55 |
DisclosureSEC source: 0001209191-21-019664 · doc4a.xml · nonDerivative · entry 3 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,376 F3 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 5, 2018. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $87.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018416 · doc4.xml · derivative · entry 2 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-03 F2 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018416 · doc4.xml · nonDerivative · entry 1 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,042 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| March 03, 2021 Filed Mar 11, 2021 01:00 UTC Amendment | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-019664 · doc4a.xml · nonDerivative · entry 2 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,723 F2 · balance_after: On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021. Read SEC document |
| February 28, 2021 Filed Mar 11, 2021 01:00 UTC Amendment | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 319 | $86.97 | $27,743.43 |
DisclosureSEC source: 0001209191-21-019664 · doc4a.xml · nonDerivative · entry 1 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,723 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. F2 · balance_after: On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021. Read SEC document |
| December 14, 2020 Filed Dec 15, 2020 01:03 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 25,000 | $0.00 Strike: $169.54 | $0.00 |
DisclosureSEC source: 0001209191-20-063359 · doc4.xml · derivative · entry 1 Estepan Ian Michael · CIK 0001836254 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-12-14 F1 · derivative.exercise_date: Twenty-five percent of the shares of common stock underlying the option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares of common stock underlying such option shall vest and become exercisable on each monthly anniversary of such date of grant thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.